Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05506046 · ClinicalTrials.gov registry record · NA
Messages About Reduced Nicotine in Combusted Tobacco Products
A NA study, sponsored by Georgia State University.
- Completed
- Registry status
- NA
- Development phase
- 1,901
- Enrollment target
NCT05506046: Completed NA study, sponsored by Georgia State University.
NCT05506046 is a NA study that has completed, run by Georgia State University. The registered enrollment target is 1,901 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05506046, a NA study, has completed, sponsored by Georgia State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,901 participants
- Enrollment target
Study Summary
The investigators will conduct a message-exposure experiment with nationally representative samples of smokers, dual-users (cigarettes and e-cigarettes), and young adult non-smokers (aged 18-29). Experimental messages will address the reduction of nicotine in cigarettes. Participants will also complete a follow-up survey after 2 weeks, measuring their recall of the messages and behaviors since message exposure.
Primary Outcome
Measured with a single item, assesses participant's perception of own risk of overall harm to health under conditions of smoking reduced nicotine cigarettes every day. Response options range from 1 (Not at all likely) to 5 (Extremely likely), with higher scores representing a better outcome. An additional option, "Don't know", is also provided.
Interventions
- BEHAVIORAL Reduced nicotine message exposure
- BEHAVIORAL Modified risk message exposure
- BEHAVIORAL Combined message exposure (reduced nicotine + modified risk)
- BEHAVIORAL Control message exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,901 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2023-02-28 |
| Phase | NA |
What the finished NCT05506046 record still lists
NCT05506046 is an interventional study that assigns participants to a tested intervention. Its 1,901 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 4 interventions - of which Reduced nicotine message exposure is the first listed.
NCT05506046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05506046 about?
NCT05506046 is a clinical study titled "Messages About Reduced Nicotine in Combusted Tobacco Products". The investigators will conduct a message-exposure experiment with nationally representative samples of smokers, dual-users (cigarettes and e-cigarettes), and young adult non-smokers (aged 18-29). Experimental messages will address the reduction of nicotine in cigarettes. Participants will also comp...
What is the current status of trial NCT05506046?
This trial is currently completed. It is a NA study. The enrollment target is 1,901 participants. The study started on 2022-10-12. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT05506046?
The interventions under investigation include: Reduced nicotine message exposure (BEHAVIORAL), Modified risk message exposure (BEHAVIORAL), Combined message exposure (reduced nicotine + modified risk) (BEHAVIORAL), Control message exposure (BEHAVIORAL).
Who is sponsoring clinical trial NCT05506046?
This trial is sponsored by Georgia State University, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05506046's enrollment target sits among peer trials
1,901 55th of 2000 higher than 1,946 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI